Fulcrum Therapeutics Inc (FULC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Fulcrum Therapeutics Inc stock (FULC) is currently trading at $6.70. Fulcrum Therapeutics Inc PS ratio (Price-to-Sales) is 2.66. Analyst consensus price target for FULC is $19.00. WallStSmart rates FULC as Sell.
- FULC PE ratio analysis and historical PE chart
- FULC PS ratio (Price-to-Sales) history and trend
- FULC intrinsic value — DCF, Graham Number, EPV models
- FULC stock price prediction 2025 2026 2027 2028 2029 2030
- FULC fair value vs current price
- FULC insider transactions and insider buying
- Is FULC undervalued or overvalued?
- Fulcrum Therapeutics Inc financial analysis — revenue, earnings, cash flow
- FULC Piotroski F-Score and Altman Z-Score
- FULC analyst price target and Smart Rating
Fulcrum Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Fulcrum Therapeutics Inc (FULC) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and revenue growth. Significant fundamental concerns warrant caution or avoidance.
Fulcrum Therapeutics Inc (FULC) Key Strengths (2)
101.55% of shares held by major funds and institutions
Trading at 1.30x book value, attractively priced
Supporting Valuation Data
Fulcrum Therapeutics Inc (FULC) Areas to Watch (4)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.66x sales
Supporting Valuation Data
Fulcrum Therapeutics Inc (FULC) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.30) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Market Cap. Some valuation metrics including Price/Sales (2.66) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -25.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -25.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
FULC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
FULC's Price-to-Sales ratio of 2.66x trades 23% below its historical average of 3.46x (0th percentile). The current valuation is 51% below its historical high of 5.46x set in Mar 2026, and 0% above its historical low of 2.66x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Fulcrum Therapeutics Inc (FULC) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Fulcrum Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -17M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 3.29, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Fulcrum Therapeutics Inc.
Bottom Line
Fulcrum Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Fulcrum Therapeutics Inc(FULC)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States. The company is headquartered in Cambridge, Massachusetts.